ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment
Pharmacogenetics and Genomics2010Vol. 21(4), pp. 163–170
Citations Over TimeTop 11% of 2010 papers
Keh‐Ming Lin, Yen‐Feng Chiu, I‐Ju Tsai, Chia‐Hui Chen, Winston W. Shen, Shu Chih Liu, Shao‐Chun Lu, Chia-Yih Liu, Mei-Chun Hsiao, Hwa‐Sheng Tang, Shen‐Ing Liu, Liang-Huey Chang, Chi‐Shin Wu, Hsiao‐Hui Tsou, Ming‐Hsien Tsai, Chun‐Yu Chen, Sumei Wang, Hsiang‐Wei Kuo, Ya‐Ting Hsu, Yu‐Li Liu
Abstract
Our findings suggest that single nucleotide polymorphisms in the ABCB1 gene may be indicators of the severity of depression and of the likely S-CIT treatment remission response in MDD.
Related Papers
- → Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study(2015)4 cited
- → Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.(2017)4 cited
- → Therapeutic effects of exercise, escitalopram, and exercise-accompanied escitalopram on brain functions in rats with depression(2021)2 cited
- → PMH25 COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS VENLAFAXINE IN SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN SWEDEN(2009)
- → PMH52 ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD)(2010)